Robotic Colorectal Surgery in 2026: What Recent Trials Now Show
Robotic colorectal surgery has crossed a turning point: long-term REAL trial outcomes now suggest oncologic benefits in mid-to-low rectal cancer, while cost and operative time remain trade-offs. Here is what the evidence shows in 2026.
Why Robotic Colorectal Surgery Is in the News Right Now
Robotic colorectal surgery has dominated surgical conferences in 2025 and 2026 because, for the first time, a randomized trial has reported long-term oncologic outcomes favoring robotic over laparoscopic resection. The three-year REAL trial follow-up, published in JAMA in June 2025, showed lower locoregional recurrence with robotic surgery for middle and low rectal cancer.
December 2025 brought another inflection point: the FDA cleared Medtronic’s Hugo platform for U.S. hospital sale, ending da Vinci’s effective monopoly and reshaping the cost conversation that has shadowed adoption since the 2010s. Patients are now arriving in clinic asking specifically about a robotic option — and surgeons need an answer grounded in the trial data, not the marketing.
The Background
Laparoscopic resection became the established standard after the CLASICC, COLOR II, and COREAN trials demonstrated noninferiority to open surgery. The robotic platform — with three-dimensional visualization, articulated instruments offering seven degrees of freedom, and improved surgeon ergonomics — was developed in part to overcome the constraints of two-dimensional laparoscopy in the narrow male pelvis.
Key terms used below: TME = total mesorectal excision; CRM = circumferential resection margin; LAR = low anterior resection; HR = hazard ratio; OR = odds ratio; RCT = randomized controlled trial.
The Evidence So Far for Robotic Colorectal Surgery
The trial landscape divides cleanly: stronger signals for robotic colorectal surgery in pelvic operations than in colon work.
- ROLARR (JAMA 2017): 471 patients across 29 sites in 10 countries. Robotic showed no significant reduction in open-conversion rates over laparoscopic (8.1% vs 12.2%). Subgroup hints favored robotic in obesity and male patients, but the trial was underpowered.
- REAL (Lancet Gastroenterology and Hepatology 2022; JAMA 2025): 1,240 patients with mid-low rectal cancer. Three-year locoregional recurrence 1.6% (robotic) versus 4.0% (laparoscopic) — adjusted HR 0.39 (95% CI 0.19-0.80). Three-year disease-free survival 87.2% versus 83.4%; overall survival not significantly different.
- Mirza et al. meta-analysis 2025 (seven RCTs, 1,731 patients): robotic reduced major complications (OR 0.70), conversion to open (OR 0.27), and CRM positivity (OR 0.62); operative time longer by 22.7 minutes; lymph node yield slightly favored laparoscopic.
Where Experts Disagree
Pro-robotic surgeons cite REAL’s long-term data, fewer conversions, and the platform’s advantage in confined pelvic anatomy as reasons to expand adoption — particularly for low rectal cancer in male or obese patients. Skeptics counter that ROLARR remains the largest Western multicenter RCT and showed no advantage, that REAL was conducted exclusively in China with experienced robotic surgeons, and that cost-effectiveness analyses repeatedly favor laparoscopy.
“really hard to move the needle on quality” — Christopher P. Childers, MD, quoted in the February 2026 ACS Bulletin, on adding robotic technology to procedures with already-strong laparoscopic outcomes
Reda Mithany, MD, and colleagues writing in Cureus argued the opposite case: complication-rate reductions and shorter stays may offset higher acquisition costs in high-volume programs, particularly for low anterior resection.
The Practical Question for Clinicians
For most colon resections — right hemicolectomy, sigmoid colectomy — laparoscopy remains efficient, well-established, and cost-effective; robotic data show minimal incremental benefit.
For mid-to-low rectal cancer, particularly in male or obese patients with narrow pelvic anatomy, robotic colorectal surgery now has the strongest evidence base of any minimally invasive option. The signal for fewer conversions and lower CRM positivity is consistent across the meta-analyses.
Surgeon experience matters more than platform. The robotic learning curve is roughly 15 to 25 cases for laparoscopically trained surgeons. Centers performing fewer than that volume per surgeon should not assume the published outcomes will translate.
What to Watch For
- Five-year REAL follow-up: whether the disease-free survival advantage of robotic colorectal surgery holds beyond three years.
- Real-world implementation: do REAL’s outcomes generalize outside high-volume academic centers?
- Cost evolution: Medtronic Hugo’s 2026 market entry may pressure consumable and platform pricing.
- Updated NCCN, ASCRS, and ESCP guidance incorporating REAL long-term data, expected through 2026-2027.
Sources
- Feng Q, Tang B, Zhang Y, et al. Robotic vs Laparoscopic Surgery for Middle and Low Rectal Cancer: The REAL Randomized Clinical Trial. JAMA. 2025 (3-year follow-up). JAMA — REAL 3-Year Outcomes (Feng et al., 2025)
- Feng Q, Yuan W, Li T, et al. Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial. Lancet Gastroenterol Hepatol. 2022;7(11):991-1004. Lancet Gastroenterology and Hepatology — REAL Short-Term Outcomes
- Jayne D, Pigazzi A, Marshall H, et al. Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer: The ROLARR Randomized Clinical Trial. JAMA. 2017;318(16):1569-1580. JAMA — ROLARR Trial (Jayne et al., 2017)
- Mirza W, Dadan S, Khan HM, Yasmin S. Robotic versus laparoscopic surgery for rectal cancer: a systematic review and meta-analysis of randomized trials. J Robot Surg. 2025;19(1):457. Journal of Robotic Surgery — 2025 Meta-Analysis (Mirza et al.)
- Fox M. Cost of Robotic Surgery Remains Complex Equation. Bulletin of the American College of Surgeons, February 2026. ACS Bulletin — Cost of Robotic Surgery (Feb 2026)
- Mithany RH, Shaikh A, Daniel N, et al. A Review of the Current Trends and Future Perspectives of Robots in Colorectal Surgery. Cureus. 2025;17(1):e77690. Cureus — Trends in Robotic Colorectal Surgery (Mithany et al., 2025)